Fri, 09 Dec 2022

NEW YORK, NY / ACCESSWIRE / October 3, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

LFST Shareholders Click Here: https://www.zlk.com/pslra-1/lifestance-health-lawsuit-loss-submission-form?prid=32345&wire=1
YSG Shareholders Click Here: https://www.zlk.com/pslra-1/yatsen-holding-loss-submission-form?prid=32345&wire=1
CNTA Shareholders Click Here: https://www.zlk.com/pslra-1/centessa-pharmaceuticals-loss-submission-form?prid=32345&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Monday, October 3, 2022, Press release picture

LifeStance Health Group, Inc. (NASDAQ:LFST)

This lawsuit is on behalf of all purchasers of LifeStance common stock pursuant and/or traceable to the documents issued in connection with LifeStance's June 10, 2021 initial public stock offering.
Lead Plaintiff Deadline : October 11, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/lifestance-health-lawsuit-loss-submission-form?prid=32345&wire=1

According to the filed complaint, (i) the number of virtual visits clients were undertaking utilizing LifeStance Health was decreasing as the COVID-19 lockdowns were being lifted, thereby flatlining LifeStance Health's out-patient/virtual revenue growth; (ii) the percentage of in-person visits clients were undertaking utilizing LifeStance Health was increasing as the COVID-19 lockdowns were being lifted, thereby causing LifeStance Health's operating expenses to increase substantially; (iii) LifeStance Health had lost a large number of physicians due to burn-out and, as a result, its physician retention rate had fallen significantly below the 87% highlighted in the initial public offering's registration statement, and LifeStance Health had been expending additional costs to onboard new physicians who were less productive than the outgoing physicians they were replacing; and (iv) as a result, LifeStance Health's business metrics and financial prospects were not as strong as the initial public offering's registration statement represented.

Yatsen Holding Limited (NYSE:YSG)

This lawsuit is on behalf of a class consisting of all persons and entities who purchased Yatsen Holding Limited American Depository Shares ('ADS') between November 19, 2020 and March 10, 2022 or acquired Yatsen ADS pursuant or traceable to documents issued in connection with Yatsen's November 2020 initial public stock offering.
Lead Plaintiff Deadline : November 22, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/yatsen-holding-loss-submission-form?prid=32345&wire=1

According to the filed complaint, the registration statement and prospectus used to effectuate the Company's initial public offering ('IPO'), Yatsen and the other named defendants misled investors into believing that Yatsen's most significant brands, Perfect Diary and Little Ondine, were thriving, thereby driving Yatsen's 'healthy' top-line growth at the time of its IPO and quarter after quarter thereafter. In truth, however, cosmetic and skincare sales of Perfect Diary and Little Ondine products were declining in the period leading up to (and including at the time of) the IPO and throughout 2021. Moreover, as the truth about Yatsen's business reached the market, the value of the Company's shares declined dramatically, causing Yatsen investors to suffer significant damages.

Centessa Pharmaceuticals plc (NASDAQ:CNTA)

This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Centessa American Depositary Shares pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about May 28, 2021; and/or (b) Centessa securities between May 28, 2021 and June 1, 2022.
Lead Plaintiff Deadline : November 28, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/centessa-pharmaceuticals-loss-submission-form?prid=32345&wire=1

According to the filed complaint, (i) the Company's product, lixivaptan, was less safe than defendants had represented; (ii) defendants overstated lixivaptan's clinical and commercial prospects; (iii) another Centessa product, ZF874, was less safe than defendants had represented; (iv) defendants overstated ZF874's clinical and commercial prospects while downplaying the drug's safety issues; and (v) as a result, documents issued in connection with Centessa's initial public offering and the Company's public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/718518/CLASS-ACTION-UPDATE-for-LFST-YSG-and-CNTA-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

More Oklahoma City News

Access More

Sign up for Oklahoma City News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!